IAS Highlights 2026
You can now see the webbinar from IAS Highlights 2026 here.
This webinar presents key highlights from the AIDS 2026 conference in Rio de Janeiro. Marta Boffito highlights new pharmacokinetic data and drug interactions for modern HIV medications, as well as how the VOGUE study demonstrates that the dolutegravir/lamivudine combination is non-inferior to bictegravir/emtricitabine/TAF in treatment-naïve patients, even with high initial viral loads. Paul Sax presents promising results from the blinded ISLAND trials, confirming that a new weekly combination of islatravir and lenacapavir is a safe and effective alternative to daily oral therapy for virologically suppressed patients. Furthermore, the complex ethical challenges in prevention research (PrEP) are addressed, particularly a South African study on broadly neutralizing antibodies (bnAbs) that faced criticism for using a placebo arm when effective oral PrEP is already available. Finally, two new cure cases are discussed in which patients with hematological malignancies achieved long-term viral remission following stem cell transplantation with the CCR5-delta32 mutation; however, one case was complicated by hepatitis B reactivation.
(this summary is AI generated and not proofread)
Speakers
Prof. Paul E. Sax
Professor of Medicine, Harvard Medical School. Clinical Director HIV Program and Division of Infectious Diseases, Brigham and Women’s Hospital Boston, MA
Prof. Marta Boffito
Consultant physician at Chelsea and Westminster Hospital and Imperial College London, London, UK
Moderator
Prof. Magnus Gisslén
Professor of Infectious Diseases Sahlgrenska Academy at University of Gothenburg, Sweden
Supported by an educational grant from ViiV Healthcare
Keywords:
AIDS 2026 (Rio de Janeiro)
Dolutegravir/Lamivudine (VOGUE study)
Weekly treatment (Islatravir/Lenacapavir, ISLAND trials)
PrEP (Pre-Exposure Prophylaxis, bnAbs)
HIV cure (Stem cell transplantation)